Recombinant Vaccines Market Research Report – Forecast to 2030

Recombinant Vaccines Market Information: By Product (Subunit Recombinant and Attenuated Recombinant Vaccines), by Disease (Cancer, Pneumococcal Disease, Hepatitis B, and DPT), and End-Users (Pediatrics, Adults, and Veterinary) – Forecast Till 2030

ID: MRFR/Pharma/4672-HCR | | Region: Global | 100 Pages         

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Recombinant Vaccines Market, by Route of Administration

6.1 Introduction

6.2 Intramuscular and Subcutaneous Administration

β€’ Market Estimates & Forecast, 2020–2027

β€’ Market Estimates & Forecast, by Region/Country, 2020–2027

6.3 Oral Administration

β€’ Market Estimates & Forecast, 2020–2027

β€’ Market Estimates & Forecast, by Region/Country, 2020–2027

6.4 Other Routes of Administration

β€’ Market Estimates & Forecast, 2020–2027

β€’ Market Estimates & Forecast, by Region/Country, 2020–2027

7. Global Recombinant Vaccines Market, by Type

7.1 Introduction

7.2 Subunit recombinant vaccines

β€’ Market Estimates & Forecast, 2020–2027

β€’ Market Estimates & Forecast, by Region/Country, 2020–2027

7.3 Attenuated recombinant vaccines

β€’ Market Estimates & Forecast, 2020–2027

β€’ Market Estimates & Forecast, by Region/Country, 2020–2027

7.4 Vector recombinant vaccines

β€’ Market Estimates & Forecast, 2020–2027

β€’ Market Estimates & Forecast, by Region/Country, 2020–2027

8. Global Recombinant Vaccines Market, by Disease

8.1 Introduction

8.2 Pneumococcal Disease

β€’ Market Estimates & Forecast, 2020–2027

β€’ Market Estimates & Forecast, by Region/Country, 2020–2027

8.3 Cancer

β€’ Market Estimates & Forecast, 2020–2027

β€’ Market Estimates & Forecast, by Region/Country, 2020–2027

8.4 Hepatitis B

β€’ Market Estimates & Forecast, 2020–2027

β€’ Market Estimates & Forecast, by Region/Country, 2020–2027

8.5 Influenza

β€’ Market Estimates & Forecast, 2020–2027

β€’ Market Estimates & Forecast, by Region/Country, 2020–2027

8.6 HPV (Human papillomavirus)

β€’ Market Estimates & Forecast, 2020–2027

β€’ Market Estimates & Forecast, by Region/Country, 2020–2027

8.7 DPT

β€’ Market Estimates & Forecast, 2020–2027

β€’ Market Estimates & Forecast, by Region/Country, 2020–2027

8.8 Others

β€’ Market Estimates & Forecast, 2020–2027

β€’ Market Estimates & Forecast, by Region/Country, 2020–2027

9. Global Recombinant Vaccines Market, by End-User

9.1 Introduction

9.2 Hospitals & Clinics

β€’ Market Estimates & Forecast, 2020–2027

β€’ Market Estimates & Forecast, by Region/Country, 2020–2027

9.3 Pediatrics

β€’ Market Estimates & Forecast, 2020–2027

β€’ Market Estimates & Forecast, by Region/Country, 2020–2027

9.4 Adults

β€’ Market Estimates & Forecast, 2020–2027

β€’ Market Estimates & Forecast, by Region/Country, 2020–2027

9.5 Veterinary

β€’ Market Estimates & Forecast, 2020–2027

β€’ Market Estimates & Forecast, by Region/Country, 2020–2027

9.5.1 Poultry

β€’ Market Estimates & Forecast, 2020–2027

β€’ Market Estimates & Forecast, by Region/Country, 2020–2027

9.5.2 Livestock

β€’ Market Estimates & Forecast, 2020–2027

β€’ Market Estimates & Forecast, by Region/Country, 2020–2027

9.5.3 Others

β€’ Market Estimates & Forecast, 2020–2027

β€’ Market Estimates & Forecast, by Region/Country, 2020–2027

10 Global Recombinant Vaccines Market, by Region

10.1 Introduction

10.2 Americas

β€’ Market Estimates & Forecast, by Region, 2020–2027

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.2.1 North America

β€’ Market Estimates & Forecast, by Country, 2020–2027

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.2.1.1 U.S.

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.2.1.2 Canada

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.2.2 South America

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.3 Europe

β€’ Market Estimates & Forecast, by Region, 2020–2027

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.3.1 Western Europe

β€’ Market Estimates & Forecast, by Country, 2020–2027

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.1 Germany

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.2 France

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.3 U.K.

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.4 Italy

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.5 Spain

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.6 Rest of Western Europe

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.3.2 Eastern Europe

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.4 Asia Pacific

β€’ Market Estimates & Forecast, by Country, 2020–2027

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.4.1 Japan

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.4.2 China

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.4.3 India

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.4.4 Australia

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.4.5 Republic of Korea

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.4.6 Rest of Asia Pacific

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.5 The Middle East & Africa

β€’ Market Estimates & Forecast, by Region, 2020–2027

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.5.1 United Arab Emirates

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.5.2 Saudi Arabia

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.5.3 Oman

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.5.4 Kuwait

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.5.5 Qatar

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

10.5.6 Rest of the Middle East & Africa

β€’ Market Estimates & Forecast, by Type, 2020–2027

β€’ Market Estimates & Forecast, by Disease, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

12 Company Profiles

12.1 Astellas Pharma Inc

12.1.1 Company Overview

12.1.2 Route of Administration Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 CSL Limited

12.2.1 Company Overview

12.2.2 Route of Administration Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Emergent BioSolutions, Inc.

12.3.1 Company Overview

12.3.2 Route of Administration Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 GlaxoSmithKline

12.4.1 Company Overview

12.4.2 Route of Administration/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Johnson & Johnson (U.S.)

12.5.1 Company Overview

12.5.2 Route of Administration Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 Mitsubishi Tanabe Pharma Corporation

12.6.1 Company Overview

12.6.2 Route of Administration Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 Merck & Co., Inc.

12.7.1 Overview

12.7.2 Route of Administration Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Pfizer, Inc..

12.8.1 Overview

12.8.2 Route of Administration Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Sanofi Pasteur SA

12.9.1 Overview

12.9.2 Route of Administration Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 Serum Institute of India Pvt. Ltd

12.10.1 Overview

12.10.2 Route of Administration Overview

12.10.3 Financials

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.11 Bavarian Nordic

12.11.1 Overview

12.11.2 Route of Administration Overview

12.11.3 Financials

12.11.4 Key Developments

12.11.5 SWOT Analysis

12.12 Mitsubishi Tanabe Pharma Corporation

12.12.1 Overview

12.12.2 Route of Administration Overview

12.12.3 Financials

12.12.4 Key Developments

12.12.5 SWOT Analysis

12.13 Daiichi Sankyo

12.13.1 Overview

12.13.2 Route of Administration Overview

12.13.3 Financials

12.13.4 Key Developments

12.13.5 SWOT Analysis

13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Pharmaceutical Industry

14 Appendix

LIST OF TABLES

Table 1 Recombinant Vaccines Industry Synopsis, 2020–2027

Table 2 Global Recombinant Vaccines Market Estimates and Forecast, 2020–2027, (USD Million)

Table 3 Global Recombinant Vaccines Market by Region, 2020–2027, (USD Million)

Table 5 Global Recombinant Vaccines Market by Type, 2020–2027, (USD Million)

Table 6 Global Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)

Table 7 Global Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)

Table 8 North America Recombinant Vaccines Market by Type, 2020–2027, (USD Million)

Table 9 North America Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)

Table 10 North America Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)

Table 11 US Recombinant Vaccines Market by Type, 2020–2027, (USD Million)

Table 12 US Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)

Table 13 US Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)

Table 14 Canada Recombinant Vaccines Market by Type, 2020–2027, (USD Million)

Table 15 Million)

Table 16 Canada Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)

Table 17 Canada Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)

Table 18 South America Recombinant Vaccines Market by Type, 2020–2027, (USD Million)

Table 19 South America Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)

Table 20 South America Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)

Table 21 Europe Recombinant Vaccines Market by Type, 2020–2027, (USD Million)

Table 22 Europe Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)

Table 23 Europe Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)

Table 24 Western Europe Recombinant Vaccines Market by Type, 2020–2027, (USD Million)

Table 25 Western Europe Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)

Table 26 Western Europe Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)

Table 27 Eastern Europe Recombinant Vaccines Market by Type, 2020–2027, (USD Million)

Table 28 Eastern Europe Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)

Table 29 Eastern Europe Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)

Table 30 Asia Pacific Recombinant Vaccines Market by Type, 2020–2027, (USD Million)

Table 31 Asia Pacific Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)

Table 32 Asia Pacific Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)

Table 33 Middle East & Africa Recombinant Vaccines Market by Type, 2020–2027, (USD Million)

Table 34 Middle East & Africa Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)

 

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Recombinant Vaccines Market

Figure 3 Segmentation Market Dynamics for Recombinant Vaccines Market

Figure 4 Global Recombinant Vaccines Market Share, by Type 2020

Figure 5 Global Recombinant Vaccines Market Share, by End-Users, 2020

Figure 6 Global Recombinant Vaccines Market Share, by Region, 2020

Figure 7 North America Recombinant Vaccines Market Share, by Country, 2020

Figure 8 Europe Recombinant Vaccines Market Share, by Country, 2020

Figure 9 Asia Pacific Recombinant Vaccines Market Share, by Country, 2020

Figure 10 Middle East & Africa Recombinant Vaccines Market Share, by Country, 2020

Figure 11 Global Recombinant Vaccines Market: Company Share Analysis, 2020 (%)

Figure 12 Astellas Pharma Inc: Key Financials

Figure 13 Astellas Pharma Inc: Segmental Revenue

Figure 14 Astellas Pharma Inc: Geographical Revenue

Figure 15 Emergent BioSolutions, Inc.. Key Financials

Figure 16 Emergent BioSolutions, Inc.: Segmental Revenue

Figure 17 Emergent BioSolutions, Inc.: Geographical Revenue

Figure 18 Pfizer, Inc.. : Key Financials

Figure 19 Pfizer, Inc.. : Segmental Revenue

Figure 20 Pfizer, Inc.. : Geographical Revenue

Figure 21 GlaxoSmithKline: Key Financials

Figure 22 GlaxoSmithKline: Segmental Revenue

Figure 23 GlaxoSmithKline: Geographical Revenue

Figure 24 Mitsubishi Tanabe Pharma Corporation : Key Financials

Figure 25 Mitsubishi Tanabe Pharma Corporation : Segmental Revenue

Figure 26 Mitsubishi Tanabe Pharma Corporation . Geographical Revenue

Figure 29 Bavarian Nordic. Key Financials

Figure 30 Bavarian Nordic. Segmental Revenue

Figure 31 Bavarian Nordic. Geographical Revenue